Climb Bio Inc. (CLYM): Total Asset Value of Company

Graphic logo of Climb Bio, Inc. (CLYM)

The market price action visualized on the GURU.Markets platform for analysis illustrates the dynamics of Climb Bio Inc (CLYM) assets, which currently stand at 219.34. The business relies on expanding targeted treatment for systemic immune failures through clinical trials. Logistics are managed via air transport of components under strict temperature control. Consequently, Climb Bio Inc (CLYM) aims to lead the severe neurological pathology therapy sector by developing agents to eliminate dangerous B-lymphocytes.

Climb Bio Inc (CLYM) Company Total Assets: for the period 10/04/2024 - 10/28/2026

Comprehensive metric breakdowns and analytics for Climb Bio, Inc. (CLYM)

- price and consensus price forecast:
Stock Quotes climbbio.com|CLYM - Price Target Chart
- market capitalization data:
Market Valuation Climb Bio, Inc|CLYM - Enterprise Value
- book capitalization data:
Accounting Value of a Share Climb Bio|CLYM - Book Capitalization|Market Capitalization to Book Value Ratio climbbio.com|CLYM - Aggregate Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Climb Bio Inc|CLYM - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Climb Bio, Inc|CLYM - Company Aggregate Debts|Debts to Book Capitalization Climb Bio, Inc
Fundamental valuation:CLYM, climbbio.com
Finished products of Climb Bio Inc

Analyzing the aggregate of all corporate resources is critical for assessing the financial stability of Climb Bio Inc. (CLYM). This metric, calculated inversely via ROA, combines equity and liabilities to reflect the actual scale of the business. The trend in the valuation of controlled resources allows for the tracking of investment inflows from pharma behemoths. Growth in this indicator confirms the company's capitalization driven by the development of new immunotherapeutic drugs.

Competitors of Climb Bio Inc (CLYM)

ARGX (argenx.com) - Cumulative Company Assets|Aggregate Company Assets BioNTech BNTX|Total Asset Value of Company Abivax|ADMA Bio (ADMA) - Company Total Assets|Aggregate Asset Value Protagonist Corp (PTGX)|Company Total Assets IMVT (Immunovant, Inc.)|kiniksa.com - Company Total Assets|Aggregate Company Assets Grifols (GRFS)|ADPT: Aggregate Asset Value|CLDX (Celldex) - Aggregate Company Assets|Aurinia Corp (AUPH) - Cumulative Company Assets|BCRX (BioCryst) - Company Total Assets|Company Total Assets veratx.com (VERA)|Dianthus Therapeutics, Inc. (DNTH) - Cumulative Company Assets|Aggregate Asset Value Pharvaris NV (PHVS)|Company Total Assets ABCL|Tourmaline - Company Total Asset Base|PGEN: Aggregate Company Assets|PHAR: Cumulative Company Assets|NKTR (Nektar Therapeutics Inc.) - Aggregate Company Assets|Cumulative Company Assets Upstream Bio, Inc.|ZBIO (Zenas Biopharma, Inc.) - Cumulative Company Assets|Company Total Assets IMNM|Aggregate Company Assets Gossamer Bio, Inc. GOSS|Total Business Assets kalvista.com (KALV)|SEPN: Company Total Assets|Company Assets Pieris Pharma PVLA|SVRA: Company Total Assets|RIGL: Cumulative Company Assets|AnaptysBio, Inc. (ANAB) - Aggregate Company Assets|astriatx.com (ATXS) - Aggregate Company Assets|ENGN: Company Total Assets|Company Total Asset Base RAPT|Aggregate Company Assets JBIO (Aerovate Therapeutics Inc)|Cumulative Company Assets Aclaris Therapeutics, Inc (ACRS)|Company Total Assets Kyverna Therapeutics KYTX|TLSA - Aggregate Company Assets|Cumulative Company Assets Cabaletta Bio (CABA)|VTYX - Aggregate Asset Value|Theratechnologies Inc (THTX) - Company Total Assets|Avalo Therapeutics Inc (AVTX) - Aggregate Company Assets|ELDN: Company Total Assets|Company Total Asset Base AGEN|Zura Bio - Aggregate Company Assets|Company Assets aTyr Pharma Inc ATYR|Cumulative Company Assets Adagene Inc.|Aggregate Asset Value ImageneBio IMA|Company Total Assets STTK (Shattuck Therapeutics)|EQ: Company Total Asset Base|Aggregate Company Assets connectbiopharm.com|Immunic (IMUX) - Total Business Assets|Company Total Assets ATRA|Cumulative Company Assets InflaRx GmbH|Company Total Assets XFOR (X4 Pharmaceuticals)|Cumulative Company Assets ACET (adicetbio.com)|Aggregate Company Assets Celularity CELU|INMB - Aggregate Company Assets|BRNS (Barinthus Bio) - Cumulative Company Assets|KZR: Company Assets|SABS (SAB Biotherapeutics) - Aggregate Company Assets|AKTX (akaritx.com) - Cumulative Company Assets|Aggregate Company Assets Enlivex Therapeutics Ltd ENLV|Total Asset Value of Company Q32 Bio Corp|GeoVax Labs Inc (GOVX) - Company Total Assets|Aggregate Asset Value Edesa Biotech Corp (EDSA)|Company Total Assets IBIO (iBio, Inc.)|Carisma Therapeutics Inc - Company Total Assets|Aggregate Company Assets XTL Biopharmaceuticals Ltd. (XTLB)|BOLT: Aggregate Asset Value|HCWB (hcwbiologics.com) - Aggregate Company Assets|Aptevo Therapeutics Inc. (APVO) - Cumulative Company Assets|AIM (AIM ImmunoTech Inc.) - Company Total Assets|Company Total Assets Aditxt Corp (ADTX)|GRI Bio (GRI) - Cumulative Company Assets|Aggregate Asset Value XORTX Therapeutics Inc (XRTX)|Company Total Assets HIND|Revelation Biosciences Corp - Company Total Asset Base|INDP: Aggregate Company Assets|SCNI: Cumulative Company Assets|CALI (calcimedica.com) - Aggregate Company Assets|Cumulative Company Assets Affimed N.V.|ALLK (Allakos Inc) - Cumulative Company Assets|Company Total Assets HOOK|Aggregate Company Assets IGM Biosciences, Inc. IGMS|Total Business Assets iteostherapeutics.com (ITOS)|OCEA: Company Total Assets|Company Assets TC BioPharm (Holdings) Plc TCBP|THRD: Company Total Assets